Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pretargeted PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in CA19-9 Positive Cancers
NCT05737615Phase 1Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2023
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of hu5B1-TCO and 64Cu-Tz-SarAr in pancreatic cancer (PC), bladder cancer, gastrointestinal cancer and 1 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Standardized Uptake Value mean measurement at 28 months. Planned start Feb 2023; status: withdrawn.
02
Drugs
hu5B1-TCO64Cu-Tz-SarAr
03
Conditions
pancreatic cancer (PC)bladder cancergastrointestinal cancersolid tumor
Beyond the preview
Go deeper on NCT05737615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737615.